Investing.com -- Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) stock surged 23% after the FDA lifted a clinical hold on the company’s pivotal Phase 2 trial of RP-A501 for the treatment of Danon disease.

Widely followed tech analyst Dan Ives of Wedbush Securities has updated his closely watched “AI 30” list. Ives added fresh names like CrowdStrike ...

C3.ai, Inc. (NYSE: AI) is one of the AI Stocks In The Spotlight For Investors. On August 18, C3 AI and Brazilian power ...

Jack Henry (JKHY) came out with quarterly earnings of $1.75 per share, beating the Zacks Consensus Estimate of $1.46 per share. This compares to earnings of $1.38 per share a year ago. These figures ...

Palantir shares tumbled Tuesday afternoon, extending recent losses as a high-profile short seller fueled worries the stock ...

A number of stocks fell in the afternoon session after investors took some profits off the table as markets awaited signals on future monetary policy from the Federal Reserve's Jackson Hole symposium ...